Table 6 Differences in patient background and the number of participants with a BS-POP score of ≥ 15 for patients or ≥ 10 for doctors between responders and nonresponders.

From: Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment

 

Responder (n=154)

Nonresponder (n=111)

p

Patient background

Age, years, mean ± SD

68.1±11.8

69.2±13.3

0.52

Gender, male (%)/female (%)

87 (56.5)/67 (43.5)

65 (58.6)/46 (41.4)

0.83

Comorbidity of diabetes, n (%)

43 (27.9)

36 (32.4)

0.51

BS-POP (Pt ≥ 15 and Dr ≥ 10)

Pregabalin, n (%)

32/61 (52.5)

18/48 (37.5)

0.13

Mirogabalin, n (%)

16/38 (42.1)

17/25 (68.0)

0.071

Duloxetine, n (%)

17/29 (58.6)

14/25 (56.0)

1.00

Neurotropin, n (%)

9/26 (34.6)

6/13 (46.2)

0.51

Total, n (%)

69/154 (44.8)

45/111 (40.5)

0.53

  1. Data are shown as the number of applicants/total number (%).
  2. BS-POP Brief Scale for Psychiatric Problems in Orthopaedic Patients.
  3. *p<0.05.
Back to article page